FindTrial
Sign In

How does pneumatic tube transportation of thrombocyteconcentrates for transfusion purposes influence the thrombocyte in vivo function?

How does pneumatic tube transportation of thrombocyteconcentrates for transfusion purposes influence the thrombocyte in vivo function? - Thrombocyteconcentrate in vivo function after transportation.

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON34106
Enrollment
20
Registered
2010-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bloeding, opbrengst en kwaliteit van thrombocytentransfusie bleeding transfusion

Interventions

None listed

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: thrombopenia (

Exclusion criteria

Exclusion criteria: infection and sepsis, active bleeding, splenomegaly. Treatment with anticoagulants (LMWH,acetylic acid, coumarines) thrombocyte transfusion shorter than 72 hours ago

Design outcomes

Secondary

MeasureTime frame
Incidence of spontaneous bleeding irrespective TC transfusion.—

Primary

MeasureTime frame
Increment of transfuion after 1 and 24 hours (measured by number of thrombocytes and corrected ammount increment-CCI) Differences of Mean platelet volume (MPV) Whole blood impedance measurement (activated by ADP/TRAP/COLL/ASPI) CD62 Microparticles PFA-100 Thrombelastography (for fibrinolysis)—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)